A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Saved in:
| Title: | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. |
|---|---|
| Authors: | Senapati J; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Muftuoglu M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Abbas HA; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Dara SI; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Basyal M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Li L; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Naqvi K; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Pourebrahim R; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Kornblau SM; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Khoury J; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org., DiNardo CD; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2023 Jun 29; Vol. 13 (1), pp. 101. Date of Electronic Publication: 2023 Jun 29. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37386016 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Senapati+J%22">Senapati J</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Muftuoglu+M%22">Muftuoglu M</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ishizawa+J%22">Ishizawa J</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Abbas+HA%22">Abbas HA</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Loghavi+S%22">Loghavi S</searchLink>; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Borthakur+G%22">Borthakur G</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yilmaz+M%22">Yilmaz M</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Dara+SI%22">Dara SI</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Basyal+M%22">Basyal M</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Naqvi+K%22">Naqvi K</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Pourebrahim+R%22">Pourebrahim R</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Jabbour+EJ%22">Jabbour EJ</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kornblau+SM%22">Kornblau SM</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Short+NJ%22">Short NJ</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Pemmaraju+N%22">Pemmaraju N</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Garcia-Manero+G%22">Garcia-Manero G</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ravandi+F%22">Ravandi F</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Khoury+J%22">Khoury J</searchLink>; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Daver+N%22">Daver N</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kantarjian+HM%22">Kantarjian HM</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Andreeff+M%22">Andreeff M</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2023 Jun 29; Vol. 13 (1), pp. 101. <i>Date of Electronic Publication: </i>2023 Jun 29. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37386016 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-023-00871-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101 Titles: – TitleFull: A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Senapati J – PersonEntity: Name: NameFull: Muftuoglu M – PersonEntity: Name: NameFull: Ishizawa J – PersonEntity: Name: NameFull: Abbas HA – PersonEntity: Name: NameFull: Loghavi S – PersonEntity: Name: NameFull: Borthakur G – PersonEntity: Name: NameFull: Yilmaz M – PersonEntity: Name: NameFull: Issa GC – PersonEntity: Name: NameFull: Dara SI – PersonEntity: Name: NameFull: Basyal M – PersonEntity: Name: NameFull: Li L – PersonEntity: Name: NameFull: Naqvi K – PersonEntity: Name: NameFull: Pourebrahim R – PersonEntity: Name: NameFull: Jabbour EJ – PersonEntity: Name: NameFull: Kornblau SM – PersonEntity: Name: NameFull: Short NJ – PersonEntity: Name: NameFull: Pemmaraju N – PersonEntity: Name: NameFull: Garcia-Manero G – PersonEntity: Name: NameFull: Ravandi F – PersonEntity: Name: NameFull: Khoury J – PersonEntity: Name: NameFull: Daver N – PersonEntity: Name: NameFull: Kantarjian HM – PersonEntity: Name: NameFull: Andreeff M – PersonEntity: Name: NameFull: DiNardo CD IsPartOfRelationships: – BibEntity: Dates: – D: 29 M: 06 Text: 2023 Jun 29 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2044-5385 Numbering: – Type: volume Value: 13 – Type: issue Value: 1 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |
